Condition: Atherosclerotic Cardiovascular Disease · Overweight · Obesity · Sponsor: Amgen
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| Alliance For Multispecialty Research - Daphne | Daphne, Alabama, United States | Recruiting |
| Eastern Shore Research Institute | Fairhope, Alabama, United States | Recruiting |
| Heart Center Research LLC | Huntsville, Alabama, United States | Recruiting |
| Mobile Heart Specialists PC | Mobile, Alabama, United States | Recruiting |
| Syed Research Consultants LLC | Sheffield, Alabama, United States | Recruiting |
| Synexus Clinical Research US, Inc. | Phoenix, Arizona, United States | Recruiting |
| Medical Advancement Centers of Arizona | Phoenix, Arizona, United States | Recruiting |
| Valley Clinical Trials, LLC dba Flourish Research | Covina, California, United States | Recruiting |
| Velocity Clinical Research- Huntington Park | Huntington Park, California, United States | Recruiting |
| Velocity Clinical Research- Los Angeles | La Mesa, California, United States | Completed |
| Orange County Research Center | Lake Forest, California, United States | Recruiting |
| Biopharma Informatic - The Cardiovascular Center | Redding, California, United States | Recruiting |
+ 770 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.